We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

This study is currently recruiting participants.
Verified August 2017 by John A. Boockvar, Feinstein Institute for Medical Research
Sponsor:
ClinicalTrials.gov Identifier:
NCT01269853
First Posted: January 4, 2011
Last Update Posted: August 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Feinstein Institute for Medical Research
Information provided by (Responsible Party):
John A. Boockvar, Feinstein Institute for Medical Research
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)